Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00626782 · ClinicalTrials.gov registry record · Phase 2
Lucentis Versus Mitomycin C During Glaucoma Surgery
A Phase 2 study of Glaucoma, sponsored by Wills Eye.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT00626782 is a Phase 2 study of Glaucoma that has completed, run by Wills Eye. The registered enrollment target is 24 participants, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00626782, a Phase 2 study of Glaucoma, has completed, sponsored by Wills Eye.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
Does a new add on (or adjunctive) therapy used in glaucoma surgery improve the success of trabeculectomy? Ranibizumab may offer benefit similar to mitomycin C in preventing epi-scleral fibrosis while avoiding the well known complications of mytomycin C which include late bleb leaks, hypotony and infection.
Conditions Studied
Interventions
- DRUG Ranibizumab
- DRUG Mitomycin (MMC)
Study Locations (1)
Pennsylvania
- Wills Eye Hospital, Glaucoma Service - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2008-01 |
| Est. Completion | 2011-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00626782
The ClinicalTrials.gov registry entry for NCT00626782 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (97% lower). The listed sponsor is Wills Eye, which has 59 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glaucoma appearing as the primary indexed condition, and to 2 interventions - of which Ranibizumab is the first listed.
NCT00626782 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00626782 about?
NCT00626782 is a clinical study titled "Lucentis Versus Mitomycin C During Glaucoma Surgery". Does a new add on (or adjunctive) therapy used in glaucoma surgery improve the success of trabeculectomy? Ranibizumab may offer benefit similar to mitomycin C in preventing epi-scleral fibrosis while avoiding the well known complications of mytomycin C which include late bleb leaks, hypotony and inf...
What is the current status of trial NCT00626782?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2008-01. Estimated completion is 2011-04.
What conditions does trial NCT00626782 study?
This clinical trial studies the following conditions: Glaucoma.
What interventions are being tested in trial NCT00626782?
The interventions under investigation include: Ranibizumab (DRUG), Mitomycin (MMC) (DRUG).
Who is sponsoring clinical trial NCT00626782?
This trial is sponsored by Wills Eye, which has 59 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00626782 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension
RECRUITING · Phase 2
-
Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
RECRUITING · Phase 2
-
Study of NT-501 Encapsulated Cell Therapy for Glaucoma Neuroprotection and Vision Restoration
ACTIVE NOT RECRUITING · Phase 2
-
Dual Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for Glaucoma
ACTIVE NOT RECRUITING · Phase 2
-
Circadian Rhythms of Aqueous Humor Dynamics in Humans
COMPLETED · Phase 2
-
Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.